http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2659845-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26db05f349a12e10706b1e5ea02c860a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7115 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
| filingDate | 2016-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40bb98c709fdf22c78917eaae9202fe4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9184102f620b89a1f3f3e29049f0c780 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8a6e6f8bb315936d859188326f293b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deb678174864cd5d6bc62e736dcb4532 |
| publicationDate | 2018-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2659845-A1 |
| titleOfInvention | Modulation of microRNAs against type 1 myotonic dystrophy and microRNA antagonists for this |
| abstract | Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs for this. The invention provides the use of inhibitors of repressor microRNAs of the MBNL1 and / or MBNL2 genes for the manufacture of a medicament for the treatment of myotonic dystrophy 1. Inhibiting said microRNAs allows to increase the endogenous levels of the corresponding MBNL1 and / or MBNL2 proteins , thereby alleviating symptoms of the disease, especially when repressors that are expressed in the main organs affected are inhibited: skeletal muscle, heart or central nervous system organs. Inhibition of miR-23b-3p and miR-218-5p microRNAs is preferred. Antagonists of oligoribonucleotide nature or oligoribonucleotide analogs suitable for this purpose are also provided, preferably by antagonists directed against the microRNAs cited with chemical modifications that enhance their interaction with the target, their stability in vivo and their ability to penetrate the cells and be distributed by tissues and organs |
| priorityDate | 2016-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 388.